Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics, Moffitt Cancer Center to Collaborate on microRNA Cancer Diagnostics

NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics announced today that it has formed a three-year collaboration with the Moffitt Cancer Center to discover, develop, and commercialize a range of microRNA-based cancer tests.

The alliance combines Rosetta's expertise in developing and commercializing miRNA diagnostics with Moffitt's network of medical oncologists and pathologists, and will focus specifically on areas of unmet medical need.

Rosetta said it has agreed to fund research conducted by Moffitt investigators that aligns with its strategic focus. The company currently has four miRNA diagnostics on the market including ones for lung cancer, kidney cancer, mesothelioma, and determining the source of tumors of unknown origin.

Additional terms of the collaboration were not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.